BIO-TECHNE Corp Other Comprehensive Income (Loss), before Reclassifications, Net of Tax
BIO-TECHNE Corp (TECH) reported Other Comprehensive Income (Loss), before Reclassifications, Net of Tax of -$36.23 million for the 9-month period ending 2015-03-31, per its 10-Q filed 2015-05-11.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax · last filed 2015-05-11
- BIO-TECHNE Corp other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2015-03-31 was -$17.14M.
- BIO-TECHNE Corp other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2014-12-31 was -$1.50M.
- BIO-TECHNE Corp other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2014-09-30 was -$17.59M.
- BIO-TECHNE Corp other comprehensive income (loss), before reclassifications, net of tax for fiscal 2014 was -$19.32M.
| Period end | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 3 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 6 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 9 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 12 month |
|---|---|---|---|---|
| 2015-03-31 | -$17.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-11 | -$18.64M derived: sum of 2 quarters · filed 2015-05-11 | -$36.23M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | -$1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-09 | -$19.09M 10-Q · filed 2015-02-09 | ||
| 2014-09-30 | -$17.59M 10-Q · filed 2014-11-10 | |||
| 2014-06-30 | -$19.32M 10-K · filed 2014-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |